Percutaneous left atrial appendage closure using the LAmbre device in patients with atrial fibrillation and left atrial appendage thrombus

Lu-Shen Jin†, Jin-Yan Ke†, Yuan-Nan Lin†, Ling Li, Jia-Yang Fu, Yi-Lian Chen, Yi-Xuan Qiu, Xiao-Wei Li, Yang-Qi Pan and Yue-Chun Li*

Department of Cardiology, Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China

Background: Left atrial appendage closure (LAAC) is considered a valid alternative for the prevention of thromboembolic stroke in patients with persistent left atrial appendage thrombus (LAAT) despite adequate anticoagulation. However, the data on LAAC using the LAmbre device for patients with LAAT is limited. This study was performed to explore efficacy and safety as well as to share the experience of the modified LAAC procedure with the LAmbre device.

Materials and methods: A total of 7 patients with persistent LAAT despite adequate anticoagulation underwent modified LAAC with the LAmbre device between November 2019 and April 2022. Transesophageal echocardiography was performed 3 months postoperatively to detect device-related thrombosis and peridevice leak. The patients’ clinical events were evaluated during the perioperative and follow-up periods.

Results: The median age, CHA2DS2-VASc score, and HAS-BLED score of all patients were 71 [53–73], 3 [2–4], and 2 [2–3], respectively. In the procedure, a cerebral protection system was used in two patients. LAAC with the LAmbre device was successfully performed in all patients without perioperative events. During the median follow-up of 383 [325–865] days, postoperative transesophageal echocardiography was performed in six (85.7%) patients. Device-related thrombosis was detected in one (16.7%) patient, and no...
A significant peridevice leak was observed. No thromboembolic event or bleeding event occurred in any patients.

**Conclusion:** LAAC with the LAmbre device is effective and safe when performed by experienced operators in highly selected patients with LAAT after adequate anticoagulation.

**KEYWORDS**
left atrial appendage closure, left atrial appendage thrombus, LAmbre device, left atrial appendage, atrial fibrillation

### Introduction

Atrial fibrillation (AF) is the most prevalent arrhythmia with an increased risk of atrial thrombosis, which forms most commonly in the left atrial appendage (LAA) in patients with non-valvular AF (1). Therefore, anticoagulation therapy is recommended for patients with AF to prevent stroke (2, 3). However, even with continuous anticoagulation, left atrial thrombus formation is still detected in a portion of patients (4–6). For these patients, intensification of antithrombotic therapy or surgical excision/occlusion of LAA was traditionally considered the only valid alternative treatment, as the presence of LAA thrombus (LAAT) was previously recognized as a contraindication to LAA closure (LAAC) (7, 8). Recently, several case reports have described the LAAC procedure in patients with persistent LAAT and suggested that it may be a valid alternative for these patients (9). However, most case reports focused on the Amplatzer cardiac plug and Amulet devices. As a widely used LAAC device, there is limited data on LAAC using the LAmbre (Lifetech Scientific Corporation, Shenzhen, China) device in patients with both AF and LAAT. The present study was performed to investigate the efficacy and safety of the modified LAAC procedure using the LAmbre device in patients with LAAT and to share our experience of this procedure.

### The LAmbre device

The LAmbre is a self-expanding device consisting of an umbrella and a cover compliantly connected by a short central waist. The umbrella was specially designed for complete collapse and repositioning, which consists of 8 claws with separate stabilizing hooks for attachment to the LAA wall. The disk is larger than the umbrella, covers the LAA ostium, and sits alongside the chamber wall under mild tension. There are several sizes of umbrellas available, ranging from 16 to 36 mm in diameter, to accommodate variations of LAA anatomy.

### Procedure

The procedures were performed under general anesthesia or local anesthesia. TEE was performed preoperatively to determine the location of the thrombus in relation to the LAA and the diameter of the device landing zone and LAA ostium. If any part of the thrombus was located between the landing zone and the LAA ostium, it was considered a proximal LAAT; otherwise, it was considered a distal LAAT. The choice of the device size and whether to use the cerebral protection system (Emboshield NAV6; Abbott Laboratories, Abbott Park, IL, USA) were at the discretion of the operator based on the TEE images. If the cerebral protection system was absent, a neurologic specialist would prepare for interventional treatment during the entire procedure. The procedure steps are as follows: (1) Transseptal access was obtained via the right femoral vein under fluoroscopic guidance, and a guidewire was slowly advanced into the left atrium. (2) The operator turned the Swartz sheath clockwise to facilitate the advancement of the guidewire into the left superior pulmonary vein. The guidewire must be manipulated carefully to avoid insertion of the LAA and contact with the LAAT. (3) The operator dropped the pigtail catheter to the LAA ostium by slowly pulling the sheath and catheter back. Unlike the conventional LAAC procedure, the operator must keep the pigtail catheter in the sheath opening during this step to avoid
random movement leading to thrombus dislodgement. (5) If the locational relationship between the pigtail catheter and the thrombus was appropriate, a small amount of contrast was injected to confirm the LAA anatomy. Intraoperative TEE was performed to reconfirm the location of the LAAT and accurately measure the LAA ostium and landing zone diameters for precise selection of the device size, which is critical to achieve a one-shot release. (6) The umbrella of the LAmbré device was initially two-thirds deployed at the ostium of LAA, and the whole system was then propelled under counterclockwise rotation to lock up the thrombus by pushing it to the distal part of the LAA. After advancement to the landing zone, the device subsequently completed deployment. The sheath was withdrawn to expand the proximal cover. (7) TEE, fluoroscopy, and a sustained tug test were then performed to confirm the proper position of the device and complete occlusion of the LAA. Finally, the device was released (Figure 1 and Supplementary Videos 1–12).

**Anticoagulation and follow-up**

After the procedure, the patients received rivaroxaban or warfarin for 3 months based on the oral anticoagulants taken preoperatively. If TEE showed satisfactory positioning of the LAmbré device, a peridevice leak of <3 mm, and no device-related thrombosis (DRT) at 3 months postoperatively, oral anticoagulants would be replaced by clopidogrel in the long term. For patients with DRT, anticoagulants were continued until follow-up TEE detected the dissolution of DRT. The patients were evaluated for the development of transient ischemic attack, stroke, systemic embolism, and major bleeding events throughout follow-up. These events were defined according to the Munich consensus document (10).

**Statistics**

Statistics analysis was performed with SPSS software, version 26.0 (IBM Corp., Armonk, NY). Numbers are shown as median [interquartile range].

**Results**

**Patient characteristics**

Seven patients (Patients A–G) were included in this study. Their baseline characteristics are shown in Table 1. The median age, CHA2DS2-VASc score, and HAS-BLED score of patients were 71 [53–73], 3 [2–4], and 2 [2–3], respectively. Patient B had paroxysmal AF, whereas all other patients had persistent AF. All patients who presented with persistent LAAT had received adequate anticoagulation therapy for at least 3 months after thrombus detection, involving warfarin (international normalized ratio 2.0–3.0) and standard doses of rivaroxaban according to creatinine clearance. The thrombus in Patients A, E, F, and G was located proximal to the LAA, whereas the thrombus in the other patients was located distal to the LAA (Figure 2).

**Procedural outcomes**

Patients D and E underwent general anesthesia due to intolerance of TEE, while the other patients received local anesthesia. The cerebral protection system was only used in Patients A and E, in which case no thrombus was collected. The LAmbré device was successfully implanted (Figure 3) in the first attempt in all patients except Patient B (Table 2). During the procedure in Patient B of “cauliflower” LAA, the partially deployed device did not successfully reach the landing zone and showed significant displacement after deployment. As the operator retracted the device slowly with TEE monitoring the state of the thrombus, the LAmbré device was completely retrieved without thrombus dislodgement. The operator then selected the upper lobe as the landing zone and advanced the catheter close to the superior edge of the LAA to avoid touching the thrombus. Finally, the LAmbré device was successfully released to complete LAAC. The median length of stay for all patients was 2 days. No major bleeding, pericardial effusion, or embolization events were observed during the peri-procedural period (Table 3).

**Follow-up**

The median follow-up duration was 383 [325–865] days. The anticoagulation regimen for patients after the procedure is shown in Table 3. TEE was performed 3 months after the procedure in all patients except Patient D, who refused TEE because of intolerance. The peridevice leaks of ≤2 mm were found in Patients A, B, and E, and no DRT was detected. At 14 months postoperatively, Patient B underwent a repeat TEE examination because of discontinuation of clopidogrel for 2 months without authorization, and a DRT (17 × 7 mm) was found. The physician changed Patient B’s regimen to 2.5 mg warfarin once daily to dissolve the DRT. After 5 months on warfarin, TEE reexamination showed complete dissolution of the DRT (Figure 4). During follow-up, no bleeding event, cerebrovascular event, or death occurred in any patients (Table 4).

**Discussion**

This study explored the effect of the modified LAAC procedure with the LAmbré device in patients with
persistent thrombosis despite long-term anticoagulation therapy. Successful LAAC was performed without thrombus dislodgement in all patients of this study. No clinical complications occurred during the periprocedural or follow-up period, although DRT was confirmed in one patient.

Left atrial appendage closure with left atrial appendage thrombus

Previous studies have shown that in the presence of adequate anticoagulation, the thrombus dissolved in only 76–79% of patients with LAAT (11, 12). For these patients with persistent LAAT and a high risk of embolic events, invasive approaches such as surgical removal of LAAT with LAA excision have been recommended to prevent stroke. However, the drawbacks of open surgery are obvious, including serious trauma, high adverse event rates, and a longer time to recover, particularly unbearable for elderly patients. In this scenario, LAAC may be a better option as a minimally invasive procedure. Several case reports have recently confirmed the effectiveness of LAAC in patients with LAAT (9). Nevertheless, the data on LAAC using the LAmbre device for patients with LAAT is limited. To the best of our knowledge, the present study is the largest study to explore the efficacy and safety of the modified LAAC procedure with the LAmbre device in patients with LAAT, as well as to share the experience of the procedure.

### Table 1 Patient characteristics.

| Patient | Male | Age | CHA2DS2-VASc | HAS-BLED | Hypertension | Diabetes mellitus | LVEF | Liver disease | Vascular Diseases | Bleeding history | Prior stroke/TIA | AF type | Location of LAAT | LAA morphology | Anticoagulants | Location of LAAT | LAA morphology |
|---------|------|-----|--------------|----------|--------------|------------------|------|---------------|------------------|-----------------|----------------|---------|----------------|----------------|---------------|----------------|----------------|----------------|
| A       | Yes  | 72  | 4            | 2        | No           | No               | 66   | No            | No               | Yes             | Yes           | Persistent | The proximal of LAA | Cauliflower | 1.875 mg warfarin | The distal of LAA | Chicken wing |
| B       | Yes  | 47  | 4            | 3        | Yes          | Yes              | 62   | No            | No               | Yes             | Yes           | Paroxysmal | The distal of LAA | Cauliflower | 20 mg rivaroxaban | The distal of LAA | Cauliflower |
| C       | Yes  | 68  | 2            | 2        | No           | No               | 63   | No            | No               | No              | No            | Persistent | The distal of LAA | Cauliflower | 20 mg rivaroxaban | The distal of LAA | Cauliflower |
| D       | Yes  | 71  | 3            | 2        | Yes          | No               | 65   | No            | No               | No              | No            | Persistent | The proximal of LAA | Cauliflower | 2.5 mg warfarin  | The proximal of LAA | Cauliflower |
| E       | Yes  | 73  | 2            | 2        | No           | Yes              | 68   | No            | No               | Yes             | No            | Persistent | The proximal of LAA | Cauliflower | 15 mg rivaroxaban | The proximal of LAA | Cauliflower |
| F       | Yes  | 74  | 1            | 1        | Yes          | Yes              | 30   | No            | No               | No              | No            | Persistent | The proximal of LAA | Cauliflower | 20 mg rivaroxaban | The proximal of LAA | Cauliflower |

AF, atrial fibrillation; LAAT, left atrial appendage thrombus; LVEF, left ventricular ejection fraction; TIA, transient ischemic attacks.
FIGURE 2
Transesophageal echocardiography images of patient (A–G) with left atrial appendage thrombus before left atrial appendage closure.

FIGURE 3
Transesophageal echocardiography images in patient (A–G) after left atrial appendage closure. The red arrows point to devices.

TABLE 2 Procedural characteristics.

| Patient | A | B | C | D | E | F | G |
|---------|---|---|---|---|---|---|---|
| Anesthesia protocol | Local | Local | Local | General | General | Local | Local |
| Device size | 30/36 mm | 16/30 mm | 22/28 mm | 26/32 mm | 30/36 mm | 24/30 mm | 28/34 mm |
| Device deployed on the first attempt | Yes | No | Yes | Yes | Yes | Yes | Yes |
| Cerebral protection device use | Yes | No | No | No | Yes | No | No |
| Procedural success | Yes | Yes | Yes | Yes | Yes | Yes | Yes |

Advantages of the LAmbre device

The LAmbre device is divided into a distal umbrella and a proximal cover, which is designed for proximal implantation. The umbrella of the device can be partially deployed at the ostium of the appendage and pushed inward to prevent embolism by propelling the thrombus to the distal LAA. During the operation, the delivery sheath does not reach the distal LAA.
TABLE 3 Periprocedural outcomes.

| Patient | A | B | C | D | E | F | G |
|---------|---|---|---|---|---|---|---|
| In-hospital days after procedure | 3 | 3 | 3 | 2 | 2 | 2 | 3 |
| Anticoagulants | 1.875 mg warfarin | 20 mg rivaroxaban | 20 mg rivaroxaban | 2.5 mg warfarin | 2.5 mg warfarin | 15 mg rivaroxaban | 20 mg rivaroxaban |
| Death | No | No | No | No | No | No | No |
| Bleeding | No | No | No | No | No | No | No |
| Embolization | No | No | No | No | No | No | No |
| Pericardial effusion | No | No | No | No | No | No | No |
| Vascular complications | No | No | No | No | No | No | No |
| Perdevice leak | ≤2 mm | No | No | No | No | No | No |

FIGURE 4
In the transesophageal echocardiography images of patient B, (A) DRT of 17*7 mm was detected 14 months postoperatively, and (B) DRT dissolved after 5 months of 2.5 mg warfarin once daily.

position, thus effectively reducing the possibility of contact with the thrombus. In contrast, the Watchman device, a widely used conventional "plug" device, requires the delivery sheath to reach more deeply into the LAA during the procedure, potentially leading to thrombus dislodgement. Other "disk" devices, such as the Amplatzer cardiac plug and Amulet device, also allow this operation. However, the LAmbre device is available in a variety of sizes and adjustable sheaths to accommodate various LAA morphologies, especially shallow or multilobular LAA anatomies (13, 14).

Characteristics of the procedure

In patients with thrombosis undergoing LAAC, the site and size of the thrombus are associated with the risk of the procedure. A thrombus close to the apex of the LAA is less likely to be contacted, implying a lower risk of thrombus dislodgement. For a proximal thrombus in the LAA, the procedure also has a relatively high success rate and safety if the thrombus is small and easy to push distally. However, some thrombi, such as large thrombi overhanging the LAA and long strips of thrombi attached to the LAA are not suitable for LAAC because it cannot be safely and effectively pushed to the distal part of the LAA. Therefore, in previous case reports of LAAC for the treatment of LAAT, the majority of patients had thrombi located distal to the LAA (9). A few studies of LACC included patients with proximal thrombi, whereas patients with thrombi overhanging the ostium were often excluded (15–18). In the present study, the thrombus in four of seven...
patients with LAAT was located proximal to the LAA, which is associated with a high risk of thromboembolic events. As a result of a detailed preoperative evaluation and an appropriate procedure performed by experienced operators, none of the patients in this study developed thrombus dislodgement or other complications.

Most of the patients in our study received local anesthesia. Under local anesthesia, the operator and the neurologist can stay informed of the patient’s neurological condition and take prompt action in case of cerebral embolism. Therefore, local anesthesia is recommended for the modified LAAC procedure unless the patient cannot tolerate TEE.

During the LAAC procedure, manipulation within the LA must be minimized to ensure safety. In some case reports of LAAC for treatment of LAAT, contrast injection, which was used for measurement of LAA size and morphology in the conventional LAAC procedure (19), was often omitted to prevent thrombus dislodgement. The operators in these reports performed the implantation based on TEE imaging (17, 20, 21). In other reports, the operators took the approach of injecting a small amount of contrast with the pigtail catheter placed shallowly into the LAA (18, 22, 23). In the present study, the operator dropped the pigtail catheter to the LAA ostium by withdrawing it after having replaced it in the left upper pulmonary vein. A small amount of contrast was injected if the locational relationship between the thrombus and pigtail catheter was appropriate. No embolism or stroke event occurred throughout the perioperative period. The moderate utilization of small amounts of contrast contributed to the success of the modified LAAC procedure without leading to intraoperative embolization.

For patients with thrombi, a one-shot release is desired to avoid complications because there is an increased risk of thrombus dislodgement during device repositioning or replacement. In Patient B of the present study, the device was confirmed unstable by a sustained tug test during the procedure. The operator had to replace the device for a successful LAAC. After retracting the cover and returning the umbrella to a partially open state, the operator confirmed no thrombus displacement and then gradually retracted the umbrella under TEE monitoring. This case provides a reference for LAAC when the thrombus impairs the stability of the device. Notably, however, our operator had extensive experience in performing LAAC, and this procedure had a high risk of thromboembolic events.

In this study, a cerebral protection system consisting of a filter composed of 120 µm micropores and a filter delivery wire was used in Patients A and E. The operator inserted 6F sheaths and deployed two filters into both internal carotid arteries through the femoral arteries to prevent devastating stroke complications. Previous studies have demonstrated the effectiveness of the cerebral protection system for peri procedural stroke prevention in patients with LAAT (16, 24, 25). However, despite the implantation of such a protection system, cerebral ischemic events still cannot be completely eliminated because the vertebral artery is unprotected. Embolic events can also occur in peripheral arteries, such as lower extremity arteries, mesenteric arteries, and renal arteries. In addition, prolongation of the operation and additional device manipulation in the carotid artery increase the risk of perioperative complications. The extra financial burden limits the use of such devices in selected patients. Indeed, because the utilization of a cerebral protection system depends on the operators’ experience and skill, there is no standard to be followed. The operators in this study considered it appropriate to deploy the cerebral protection system in patients with LAAT close to the ostium because these patients were prone to thrombus dislodgement. It must be emphasized that if a cerebral protection system is unavailable, a neurologic specialist must be prepared for interventional treatment during the entire procedure.

Follow-up

In our study, no thromboembolic or bleeding events occurred in any patient during the median follow-up of 383 [325–865] days. According to the HAS-BLED score and CHA2DS2-VASc score, the incidence of major bleeding events and the incidence of thromboembolic events were both reduced by 100% in our study compared with the expected annual rate (26). However, the risk of thromboembolic events in our study might be higher than that in previous studies because our patients had persistent thrombi despite anticoagulation therapy.

In the postoperative TEE screenings of six patients, DRT was detected in the second TEE screening of Patient B at 14 months after the procedure. This may be due to his discontinuation of clopidogrel. After treatment with warfarin for 5 months, the repeat TEE confirmed the dissolution of the DRT, and no clinical events occurred. These results reflect the efficacy and safety of LAAC in patients with LAAT. However, the long-term effect and safety require confirmation.

Limitations

This study has three main limitations. First, it was a single-center retrospective study with a small sample size. The results are not generalizable because the patients who underwent the modified procedure were highly selected and the operators were experienced. Second, patients with silent brain ischemia and subclinical microembolization could not be excluded because brain magnetic resonance imaging and neurologic assessment were not performed. Thirdly, the anticoagulation therapy after LAAC was not identical in patients, which may affect the incidence of DRT. Finally, the risk of long-term complications is unclear due to a relatively short follow-up duration.
Conclusion

This study has shown that the modified LAAC procedure with the LAmbre device is safe and effective in selected patients with LAAT when performed by experienced operators. This procedure might be an option for patients with AF and LAAT in whom oral anticoagulants are ineffective. However, large randomized studies with long-term follow-up are required to confirm the safety and efficacy.

Data availability statement

The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Acknowledgments

We thank Angela Morben, DVM, ELS, from Liwen Bianji (Edanz) (www.liwenbianji.cn), for editing the English text of a draft of this manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.1071119/full#supplementary-material

References

1. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. (1996) 61:755–9. doi: 10.1016/0003-4975(95)00887-X

2. Hindricks G, Poppala T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS). Eur Heart J. (2021) 42:373–498.

3. Kakkar AK, Mueller I, Bassand JF, Fitzmaurice DA, Goldhaber SZ, Goto S, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. (2013) 8:e63479. doi: 10.1371/journal.pone.0063479

4. Reers S, Karanatsios G, Borowski M, Kellner M, Reppel M, Waltenberger J. Frequency of atrial thrombus formation in patients with atrial fibrillation under treatment with non-vitamin K oral anticoagulants in comparison to vitamin K antagonists: a systematic review and meta-analysis. Eur J Med Res. (2018) 23:49. doi: 10.1186/s40001-018-0350-9

5. Kawabata M, Goya M, Sasaki T, Maeda S, Shirai Y, Nishimura T, et al. Left atrial appendage thrombi formation in Japanese non-valvular atrial fibrillation patients during anticoagulation therapy — warfarin VS. Direct oral anticoagulants. Circ J. (2017) 81:645–51. doi: 10.1253/circj.CJ-16-1089

6. Frenkel D, D’Amato SA, Al-Kazaz M, Markowitz SM, Liu CF, Thomas G, et al. Prevalence of left atrial thrombus detection by transesophageal echocardiography. JACC Clin Electrophysiol. (2016) 2:295–303. doi: 10.1016/j.jacep.2016.01.004

7. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. (2009) 374:534–42. doi: 10.1016/S0140-6736(09)61343-X

8. Holmes DR, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: the PREVAIL trial. J Am Coll Cardiol. (2014) 64:1–12. doi: 10.1016/j.jacc.2014.04.029

9. Sharma SP, Cheng J, Turagam MK, Gopinathannair R, Horton R, Lam YY, et al. Feasibility of left atrial appendage occlusion in left atrial appendage thrombus. JACC Clin Electrophysiol. (2020) 6:414–24. doi: 10.1016/j.jacep.2019.11.017

10. Tzikas A, Holmes DR, Gafner S, Ruz CE, Blomstrom-Lundqvist C, Diener HC, et al. Percutaneous left atrial appendage occlusion: the Munich consensus
document on definitions, endpoints, and data collection requirements for clinical studies. *Europace.* (2017) 19:4–15. doi: 10.1093/europace/euw141

11. Hussain A, Katz WE, Genuardi MV, Bhonsale A, Jain SK, Kanchatra K, et al. Non-vitamin K oral anticoagulants versus warfarin for left atrial appendage thrombosis resolution in nonvalvular atrial fibrillation or flutter. *Pacing Clin Electrophysiol.* (2019) 42:1183–90. doi: 10.1111/pace.15765

12. Niku AD, Shota T, Siegel RJ, Rader F. Prevalence and resolution of left atrial thrombus in patients with nonvalvular atrial fibrillation and flutter with oral anticoagulation. *Am J Cardiol.* (2019) 123:63–8. doi: 10.1016/j.amjcard.2018.09.027

13. Lam YY. A new left atrial appendage occluder (Lifetech Lambretm device) for stroke prevention in atrial fibrillation. *Cardiovasc Revasc Med.* (2013) 14:134–6. doi: 10.1016/j.carrev.2013.04.003

14. Kleinecke C, Gomez Monterroso O, Scalone G, Lam YY, Shin ES, Bellmann B, et al. First-in-human experience of left atrial appendage occlusion with the steerable FuStar sheath. *J Interven Cardiol.* (2018) 31:532–7. doi: 10.1111/jioc.12509

15. Bellmann B, Rillig A, Leistner DM, Kasner M, Skurk C, Landmesser U, et al. Left atrial appendage closure in a patient with left atrial appendage thrombus using a novel fish ball technique. *Int J Cardiol.* (2017) 234:146–9. doi: 10.1016/j.ijcard.2016.12.141

16. Streb W, Mitrêga K, Podolecki T, Kowalska W, Sawicka M, Kalarus Z. Rationale for cerebral protection in patients with left atrial appendage thrombus during percutaneous left atrial appendage closure: a single-center initial experience. *Pol Arch Intern Med.* (2020) 130:202–4. doi: 10.20452/pamw.15711

17. Sahiner L, Coteli C, Kaya EB, Ates A, Kilic GS, Yorgun H, et al. Left atrial appendage occlusion in patients with thrombus in left atrial appendage. *J Invasive Cardiol.* (2020) 32:222–7.

18. Marroquin L, Tirado-Conte G, Praco N, Streb W, Gutierrez H, Boccuzzi G, et al. Management and outcomes of patients with left atrial appendage thrombus prior to percutaneous closure. *Heart.* (2021) 108:1098–106.

19. Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. *JAMA.* (2014) 312:1988–98. doi: 10.1001/jama.2014.15192

20. Jalal Z, Iriart X, Dinet ML, Selly JB, Tafer N, Renou P, et al. Extending percutaneous left atrial appendage closure indications using the amplatzerm cardiac plug device in patients with persistent left atrial appendage thrombus: the thrombus trapping technique. *Arch Cardiovasc Dis.* (2016) 109:659–66. doi: 10.1016/j.acvd.2016.02.012

21. Bordignon S, Bologna F, Chen S, Konstantinou A, Tisanakas N, Tofuku S, et al. Percutaneous left atrial appendage closure in the presence of thrombus: a feasibility report. *J Cardiovasc Electrophysiol.* (2019) 30:2858–63. doi: 10.1111/jce.14246

22. Lee OH, Uhm JS, Kim JS, Cho II, Hong GR, Pak HN, et al. Percutaneous isolation of left atrial appendage thrombus. *J Cardiol Cases.* (2017) 16:67–9. doi: 10.1016/j.jccase.2017.05.002

23. Lange M, Bult H, Wiegla H, Löffel P, Wichter T. Closure of left atrial appendage with persistent distal thrombus using an amplatzer amulet occluder. *J Invasive Cardiol.* (2016) 28:E75–6.

24. Boccuzzi GG, Montabone A, D’Ascenzo F, Colombo F, Ugo F, Muraglia S, et al. Cerebral protection in left atrial appendage closure in the presence of appendage thrombosis. *Catheter Cardiovasc Interv.* (2021) 97:511–5. doi: 10.1002/ccd.29161

25. Cammalleri V, Usio GP, Muscoli S, De Vico P, Romeo F. Transcatheter occlusion of left atrial appendage with persistent thrombus using a trans-radial embolic protection device. *J Cardiovasc Med (Hagerstown).* (2016) 17:e224. doi: 10.2459/JCM.0000000000000323

26. Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. *Eur Heart J.* (2012) 33:1500–10. doi: 10.1093/eurheartj/ehr488